Ankylosing spondylitis (AS) is a chronic inflammatory disease affects predominantly the axial skeleton. The tumor necrosis factor alpha (TNF-α) inhibitors (infliximab) is a promising treatment. This study aims to evaluate the impact of infliximab on lipid profile in AS patients. An interventional study enrolled 122 AS patients who were categorized into two groups. Group A was receiving infliximab for the first time and group B were already on treatment. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Serum total cholesterol (TC), Low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglyceride (TG) levels, and erythrocyte sedimentation rate (ESR) were assessed at baseline and after 12 weeks. In Group A, the BASDAI decreased significantly after 12 weeks of treatment. Serum TC and HDL level increased significantly, while there was an insignificant change in BASFI, LDL and TG serum level. Group B patients showed an insignificant change in the BASDAI, BASFI, TC, HDL, LDL and TG level between the two readings. Short term infliximab in AS was associated with an improvement in disease activity and increase in both cholesterol and HDL levels. However, the atherogenic index remained unchanged.
___
Khan MA. Spondyloarthropathies. Rheum Dis Clin North Am. 1992;18(1):1276.
Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimate of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41(5):778-99.
Abdelrahman MH, Mahdy S, Khanjar IA, Siam AM, Malallah HA, Al-Emadi SA, Sarakbi HA, Hammoudeh M. Prevalence of HLA-B27 in patients with ankylosing spondylitis in Qatar. Int J Rheumatol. 2012;8(6):213-6.
Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL, Taylor A, Calin A, Wordsworth P. Susceptibility to ankylosing spondylitis in twins. The role of genes, HLA, and the environment. Arthritis Rheum. 1997;40(10):1823-8.
Reveille JD. Genetics of spondyloarthritis--beyond the MHC. Nat Rev Rheumatol. 2012;8(5):296-304.
Brown MA, Brophy S, Bradbury L, Hamersma J, Timms A, Laval S, Cardon L, Calin A, Wordsworth BP. Identification of major loci controlling clinical manifestations of ankylosing spondylitis. Arthritis Rheum. 2003;48(8):2234-9.
Schett G, Landewé R, van der Heijde D. Tumour necrosis factor blockers and structural remodeling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis. 2007;66(6):709-11.
Hassan S, Milman U, Feld J, Eder L, Lavi I, Cohen S, Zisman D. Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study, Arthritis Res Ther. 2016;18(1):261.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91.
Mounach A, El Maghraoui A. Efficacy and safety of adalimumab in ankylosing spondylitis. Open Access Rheumatol. 2014;6:83-90.
Garces SP, Parreira Santos MJ, Vinagre FMR, da Silva. Anti-tumour necrosis factor agent and lipid profile a class effect? Ann Rheum Dis. 2008;67(6):895-6.
Spanakis E1, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT. The Modest but sustained increase of serum high-density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatology. 2006;33(12):2440-6.
Bozkirili E, Yucel A. Effect of infliximab treatment in terms of cardiovascular risk and insulin resistance in ankylosing spondylitis patients. Modern Rheumatology. 2014;24(2):335-9.
Kiortsis DN1, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33(5):921-3.
Moreau J, Souza F, Ribeiro A. Effect of long term TNF blockage on lipid profile in ankylosing spondylitis. Ann Rheum. 2012;71(suppl3):562.
Garcês SP, Parreira Santos MJ, Vinagre FM, Roque RM, da Silva JA. Anti – tumour necrosis factor agents and lipid profile: a class effect? Ann Rheum Dis. 2008;67(6):895-6.